Cash, cash equivalents, short- and long-term investments, and interest receivable were $639.0 million as of September 30, 2024. Cullinan continues to expect its cash resources to provide runway into 2028 based on its current operating plan.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGEM:
- Cullinan Therapeutics to present preclinical data for CLN-978
- Verizon downgraded, Canadian Pacific upgraded: Wall Street’s top analyst calls
- Cullinan Therapeutics initiated with a Buy at UBS
- Cullinan Management Advances SLE Treatment with FDA Trial
- Cullinan receives U.S. FDA clearance for IND application for CLN-978